Copenhagen, Denmark, and Cleveland, Ohio, USA, 29 April 2024 - Xellia Pharmaceuticals (‘Xellia’), a global leader in the manufacturing of specialty anti-infective treatments and critical care therapies, announces that the US Court has vacated the Modified Consent Decree imposed on Xellia’s Cleveland, Ohio facility in 2016.
The original Consent Decree for the manufacturing site was entered into by the US Food and Drug Administration (FDA) and the previous site owner, Ben Venue Laboratories, Inc. (BVL) in January 2013. Consent Decrees are site specific and do not relate to the owner. As a result, when Xellia acquired the site in November 2015, the Company entered an associated Modified Consent Decree with the FDA.
The Modified Decree sets out the processes with which Xellia must comply to conduct manufacturing activities at the Cleveland site. Since entering the Decree, Xellia’s site has been regularly inspected by FDA to determine compliance with rules and regulations.
In March 2024, Xellia received a VAI (Voluntary Action Indicated) classification, a milestone demonstrating a ‘continued state of compliance’, based on repeated positive feedback from inspections. On the back of this classification, the US Court of Law has vacated the Modified Consent Decree.
Michael Kocher, CEO at Xellia Pharmaceuticals, said:
“Our team in Cleveland has done an excellent job of navigating the FDA’s inspections over the years, providing prompt and comprehensive responses to observations and information requests. The team’s perseverance has been rewarded with the lifting of the Decree, which is great news for Xellia. Our sincere thanks to everyone at the Cleveland site.”
For more information, please contact:
Xellia Pharmaceuticals
Regitze Reeh, Vice President Corporate Communications & Public Affairs
Regitze.Reeh@xellia.com
Instinctif Partners (International media relations)
Melanie Toyne-Sewell / Katie Duffell / Feaven Abidta
+44 (0) 20 7457 2020
Email: xellia@instinctif.com